NCT05555251 - BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 28, 2022

Primary Completion Date

February 7, 2024

Study Completion Date

February 7, 2024

Conditions

HER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Metastatic Breast CancerMetastatic Gastroesophageal Junction AdenocarcinomaMetastatic Gastric Adenocarcinoma

Interventions

DRUG

BI-1607

administered at different doses in Phase I by intravenous infusions every 3 weeks.

DRUG

BI-1607

administered at the recommended dose in Phase 2a by intravenous infusions every 3 weeks.

DRUG

Trastuzumab

administered at 8mg/kg for the first infusion and at 6mg/kg in subsequent infusions by intravenous infusions every 3 weeks.

Trial Locations (6)

28034

Complejo hospitalario Ruber Juan Bravo, Madrid

45136

Evang. Kliniken Essen-Mitte, Essen

60488

Krankenhaus Nordwest, Frankfurt

08035

Hospital Vall d'Hebron, Barcelona

OX3 7LE

Churchill Hospital, Oxford

SO16 6YD

Southampton General Hospital, Southampton